



5 June 2026

Hemogenyx Pharmaceuticals plc

("Hemogenyx Pharmaceuticals" or the "Company")

Posting of Annual Report & Notice of Annual General Meeting

Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group, confirms that the Annual Report and Accounts for the year ended 31 December 2025, the Notice of the Annual General Meeting ("AGM") and a Form of Proxy will be posted to shareholders today and are available on the Company's website at <https://hemogenyx.com/investors/annual-half-year-reports/>.

The AGM is to be held on 30 June 2026 at 2.00 pm BST at One Heddon Street, London, W1B 4BD.

Enquiries:

Hemogenyx Pharmaceuticals plc

Dr Vladislav Sandler, Chief Executive Officer & Co-Founder

Peter Redmond, Director

SP Angel Corporate Finance LLP

Matthew Johnson, Vadim Alexandre, Adam Cowl

Peterhouse Capital Limited

Lucy Williams, Duncan Vasey, Charles Goodfellow

<https://hemogenyx.com>

headquarters@hemogenyx.com

peter.redmond@hemogenyx.com

Tel: +44 (0)20 3470 0470

Tel: +44 (0)20 7469 0930



About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.

The Company is a clinical-stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as platform technologies that it uses as engines for novel product development.